NVAX Stock Price and Chart — NASDAQ:NVAX — TradingView (2024)

Now what?Seems like 3.5 is a string demand area that pushes the price very hard to the upside. The last time was in Jan 2020. I don't think is going to explode above 30 but the next resistance is at 10. This is a high volatile stock, I bought calls exp 04/19 strike 5.5. If this breaks out will be massive.

NVAX will make us happy soon.1) RSI 2 moving averages will cross each other soon. Purple one 38.14 and Green one 38.69. If purple one cut above green one it will be buy sign. I am waiting for buying next year because this is monthly chart. I hope RSI's 2 moving averages will cross each other. 36.91, 35.21 and 31.72 were very im

Unpopular opinion: new cycle for NOVAVAXNovavax is, besides a big pharma stock and one of the main previous providers of COV!D vaccines, a cyclical stock.It has been for 20 years, and I'm betting 2% of my portfolio it is going to be again.Despite the latest earnings, we are in the midst of the early part of the global liquidity cycle,

NVAX, is prepping for a turnaround ERA. Massive Growth Prospect!NVAX surged an impressive 29.4% last trading day with significant volume. Net positive volume increased massively from 6.33M to 28.12M for a 344% increase. These extraordinary numbers should be telling of what's to come in the mid to long term. Buyers are back in the scene, positioning at the curr

Novavax (NVAX) - signs of potential breakout 4-hourNovavax (NVAX) - signs of potential breakout 4-hour Novavax is a clinical-stage biotechnology company developing a vaccine for influenza. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout. The stock is up over 40% in the past month, and it is

Novavax Sees 2024 Sales Flat to Lower, Plummeting By 26.4%In a quest to reclaim lost ground and assert its presence in the competitive COVID-19 vaccine market, Novavax (NASDAQ: NASDAQ:NVAX ) charts a strategic course aimed at improving commercial performance and gaining market share from industry giants Pfizer (PFE.N) and Moderna (MRNA.O).Despite facing

NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical AnalysisNVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance

NVAX rises impending an earnings report LONGToday NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earningsis coming this upcoming week. This week NVAX news release showed it had settled a years longlitigation over a failed COVID. In the face of earnings around the corner, was this news releasea coi

NVAX- a medical penny stock Buy Weakness LONGNVAX on a 120 minute chart demonstrates a trend down in the past month after a period ofconsolidation producing the POC line on the volume profile. The MACD shows some bullish divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative volume void. NVAX fell qu

Novavax- NVAX- Medical Technology Vaccine Focused LONGNVAX on the 15 minute chart has been compressing price action volatility into a symmetricaltriangle. It in now in a breakout of the triangle and in the process when from undervalued onMonday to the upper trendline and then down to the support trendline and then up again.It passed through the